Nipocalimab (Imaavy) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · e81-e83
DOI: 10.58347/tml.2026.1754g ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.
Abstract (Originalsprache)
The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab (Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The FcRn blocker rozanolixizumab (Rystiggo) was approved earlier for the same indication.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Nipocalimab (Imaavy) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics, 68(1754), e81-e83. https://doi.org/10.58347/tml.2026.1754g
Vancouver
Nipocalimab (Imaavy) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):e81-e83. doi:10.58347/tml.2026.1754g
BibTeX
@article{euvimed2026,
title = {Nipocalimab (Imaavy) for Myasthenia Gravis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1754},
pages = {e81--e83},
doi = {10.58347/tml.2026.1754g}
}
EUVIMED